世界中医药

目的:观察双轻颗粒加减联合行为干预治疗非酒精性脂肪性肝病(NAFLD)的临床疗效。方法:选取2014年6月至2015年12月上海交通大学附属第六人民医院中医科收治的NAFLD患者103例，随机区组设计分为观察组78例和对照组25例,其中观察组口服以双轻颗粒为基础方加减而成的3型5个基础方中药并联合行为干预。对照组口服血脂康并联合行为干预。2组疗程均为16周,观察2组患者临床症状、肝功能、血脂以及肝脏超声的变化。结果:观察组患者临床症状改善情况、肝功能及肝脏超声的改善均明显优于对照组(P<0.05)。综合疗效观察组总有效率为89.7%,对照组为84.0%,观察组优于对照组(P<0.05)。结论:以双轻颗粒为基础方的辨证论治中药可明显改善NAFLD患者临床征候群,并可改善肝功能,降低血脂水平,改善肝脏超声下脂肪肝水平。

English Summary:

To observe the clinical effect of Modified Shuangqing Granule with behavior intervention in treating non-alcoholic fatty liver disease (NAFLD). Methods:A total of 103 NAFLD patients were divided into treatment group with 78 cases and control group with 25 cases by randomized block design. The treatment group was treated with five prescription of traditional Chinese medicine based on Shuangqing Granule and behavioral intervention. The control group was given Xuezhikang combined with behavioral intervention. Two groups were treated for 16 weeks. The improvement in symptoms, liver function, blood lipid and liver ultrasound change of the two groups were observed. Results:The improvement of clinical symptoms, liver function and liver ultrasound of the patients in the treatment group were significantly better than those in the control group (P<0.05). The total effective rate of the treatment group was 89.7%, and 84.0% in the control group. The treatment group were better than the control group (P<0.05). Conclusion:The traditional Chinese medicine prescription evolved from Shuangqing Granule based on syndrome differentiation can obviously improve the clinical syndrome and liver function, reduce blood lipid, improve fatty liver level under ultrasound of NAFLD patients.

查看全文查看/发表评论下载PDF阅读器